Showing results (1-10 of 478) with videos related to
Sort By:
Pageof 48
Clinics in Liver Disease|November 27, 2012
Hepatitis C viral kinetics: the past, present, and futureAnushree Chatterjee, Patrick F Smith, Alan S PerelsonAntiviral Therapy|November 12, 2015
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infectionLaetitia Canini, Jeremie Guedj, Anushree Chatterjee, et al.Antiviral Therapy|November 29, 2012
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Anushree Chatterjee, Jeremie Guedj, Alan S PerelsonAntiviral Therapy|October 17, 2014
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCVLaetitia Canini, Anushree Chatterjee, Jeremie Guedj, et al.Journal of Virology|March 23, 2018
Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein MechanismsThomas R Aunins, Katherine A Marsh, Gitanjali Subramanya, et al.Antiviral Therapy|January 11, 2018
A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitorLaetitia Canini, Annabelle Lemenuel-Diot, Barbara J Brennan, et al.Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|July 22, 2015
The challenges of modelling antibody repertoire dynamics in HIV infectionShishi Luo, Alan S PerelsonHepatology (Baltimore, Md.)|March 9, 2011
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment durationJeremie Guedj, Alan S PerelsonMathematical Biosciences|November 4, 2008
Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blipsLibin Rong, Alan S PerelsonPageof 48